Gate2Brain
  • Home
  • Company
  • Team
  • Technology
  • Pipeline-Proof of Concept
  • Investors
  • News & Media
  • Contact
  • Menu Menu

Launch of Gate2Brain, the “key” to transporting drugs into the brain and improving their effectiveness

Press releases
Gate2Brain

Launch of Gate2Brain, the “key” to transporting drugs into the brain and improving their effectiveness

  • Gate2Brain technology seeks to increase the effectiveness and reduce the side effects of treatments for brain disease.
  • It is based on a research line developed at IRB Barcelona and breakthroughs made jointly with the University of Barcelona and the Sant Joan de Déu Research Institute – Hospital Sant Joan de Déu.
  • The company has been launched with the support of the Mind the Gap Programme run by the Botín Foundation, which will provide an initial investment of €500,000 and management support through an expert advisor.

Barcelona, 9 July 2020.- Researchers from IRB Barcelona, the University of Barcelona (UB) and the Sant Joan de Déu Research Institute – Hospital Sant Joan de Déu (SJD) have set up Gate2Brain, a company based on a novel technology developed at IRB Barcelona to transport drugs into the brain. Gate2Brain is the second joint spin-off between IRB Barcelona and the UB to be funded by the Mind the Gap Programme run by the Botín Foundation.

Driven by IRB Barcelona associate researcher Meritxell Teixidó, Gate2Brain combines several families of peptides able to cross the blood-brain barrier, a structure that hinders access of most drugs to the brain. “The brain is a precious organ that is strongly protected by a kind of wall. We have managed to develop “keys” that facilitate entry and that we believe could allow different drugs to enter the brain and treat diseases of this organ,” explains Teixidó, CEO of the company. The pharmaceutical industry has invested millions of euros in the development of drugs that ultimately did not cross the blood-brain barrier and have consequently been unsuccessful.

Gate2Brain has been set up to exploit the technology developed over the last 15 years in the Peptide and Protein Laboratory headed by Ernest Giralt (Professor at the UB) at IRB Barcelona, in which Teixidó is a Research Associate. The research line that Teixidó has led in recent years has produced three families of shuttle peptides with the ability to cross the blood-brain barrier and deliver therapeutic molecules to the brain that cannot cross it unaided. In addition to IRB Barcelona, ​​the UB has also participated in the development of these families of peptides, and the Sant Joan de Déu Hospital has also been involved in the development of the first product.

The advantages of this technology include the possibility to improve the effectiveness of many treatments, as well as to reduce the amount of drug administered and thus limit side effects.

 

A multidisciplinary team to drive the company’s growth

Gate2Brain has come about with an initial investment of €500,000 from the Mind the Gap Programme run by the Botín Foundation. In its previous stage, this research line was supported by “la Caixa” Foundation’s CaixaImpulse Programme, to advance with the preclinical study for a specific type of pediatric glioma. A year ago, the technology also received funding from the Agency for the Management of University and Research Grants (AGAUR) in the “Funding for the Knowledge Industry- PRODUCTE” call.

The new company will be based at the Barcelona Science Park, while the experimental work will be conducted at the Sant Joan de Déu Hospital. The company plans to advance the development of a drug to treat a type of childhood brain cancer, as well as evaluate the performance of the drug transport platform in other diseases that require therapeutic agents to cross the blood-brain barrier.

In addition to Teixidó, Gate2Brain has founding partners with a multidisciplinary profile, bringing expertise in basic peptide and protein research, pharmaceutical development, clinical expertise in pediatric oncology, and business insight to drive the company’s growth. According to Teixidó, “the company launch today is the result of the collective success of the research groups and Innovation departments, which I want to thank for their work. We have worked shoulder to shoulder during all this time to finally make the company a reality.”

 

The sixth spin-off created by IRB Barcelona to date

Transfer and innovation are key for IRB Barcelona and, since the launch of the institute, its Innovation Department has promoted the setup of six spin-offs. Its director, Francesc Posas, says, “We are very proud that nearly 15 years of research at IRB Barcelona bear fruit and have brought about a new spin-off as promising as Gate2Brain. In the coming years, we intend to continue to foster spin-offs derived from the fundamental biomedical research done in our centre—companies that will ultimately benefit patients with diseases for which there is currently no cure.”

As the unit for technology transfer and innovation at the University of Barcelona, the Bosch i Gimpera Foundation (FBG) is responsible for transferring research results to society through the creation of spin-offs, patent licensing, and through contracts with companies and institutions, thus contributing to the competitiveness of the business fabric and to the improvement of social well-being. In 2019, 826 projects were managed and received €33.85 M funding. Gate2Brain is the 46th spin-off created by the FBG-UB, 28 of which involve participation of the UB.

 

Backing from Mind the Gap

Since 2010, the Botín Foundation’s Mind the Gap Programme has been promoting entrepreneurship in the Life Sciences in order to help technologies produced by Spanish centres reach the market and generate socio-economic development. To this end, it invests financial (€500,000) and management resources, the latter through an expert advisor who provides guidance and support in the critical aspects of project viability. Since 2016, in addition to the Botín Foundation, Mind the Gap has been operating through a co-financing vehicle involving the participation of a group of private investors.

Gate2Brain joins the eight companies that already form part of the Mind the Gap Programme. To date, these companies have secured €16 M of investment. They have a combined annual turnover of €1.5 M, and in 2019 they provided 53 highly qualified jobs.


Source:
Fundación Botín
https://www.fundacionbotin.org/

July 9, 2020/by Susana Meneses
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2021/02/Captura-de-pantalla-2021-02-10-a-las-16.49.05.png 705 1448 Susana Meneses https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png Susana Meneses2020-07-09 15:52:532021-03-23 13:51:22Launch of Gate2Brain, the “key” to transporting drugs into the brain and improving their effectiveness

CATEGORIES

  • Events
  • News
  • Podcast
  • Press releases
  • Publications
  • Videos

Events

  • VII SEQT Summer School “Medicinal Chemistry and Chemical Biology in Drug DiscoveryGate2BrainGate2Brain at the VII SEQT Summer SchoolJuly 26, 2022 - 08:39
  • Thank you for inviting Gate2Brain last Friday to the conference "DIGITALIZING AND REINDUSTRIALIZING SPAIN WITH THE RECOVERY PLAN". The purpose of this conference, focused on the digital axis of the Recovery Plan, was to give visibility to some of the digitization projects that have already received funding from the Plan in different areas and that are already contributing to this transformation, as well as to present the evolution of the Digital Spain agenda.Asuntos Económicos y transformación digitalGate2Brain at “Digitalizing and reindustrializing Spain with the recovery plan”July 11, 2022 - 13:39
  • EITHealth Catapult 2022eithealthGate2Brain semifinalist of EITHealth’s Catapult 2022June 12, 2022 - 08:47
  • Gate2Brain will be attending in Basel, Switzerland, the Investment Readiness Series, a @Biocat initiative co-organized by the Delegation of the Government of Catalonia in Switzerland, The aim of the meeting is to put the best projects - from companies and/or research organizations - in contact with investors, business angels, venture capitalists and leading Swiss companies.Gate2Brain will be attending The Investment Readiness SeriesApril 26, 2022 - 17:29
  • Gate2Brain is delighted to be attending next week's #AseBioInvestorDay2022, organised by Asociación Española de Bioempresas in Madrid.Gate2BrainGate2Brain attending Asebio Investor Day 2022April 21, 2022 - 14:46

SOCIAL

  • linkedin
  • youtube

RSS RSS Ciencia

  • HIGHLIGHTS: Catalan health startups exceed 2021 investments during the first half of the year, unprecedented €100M mega-round, progress in advanced therapies, new equipment and acknowledgements July 28, 2022 biocat
  • 2021 Biocat Report of Activities: looking back on a historic time for the BioRegion July 26, 2022 biocat
  • Biocat, coordinator of two new European projects to maximize impact of innovation in BioRegion July 21, 2022 biocat
  • HIGHLIGHTS: the biggest funding round of the BioRegion, new scientific and hospital facilities, foreign investment in research, and collaborations with tech companies to improve health service provisions June 29, 2022 biocat
  • AseBio 2021 Report to highlight sector’s contribution to sustainable growth June 27, 2022 biocat
  • BioRegion pipeline and digital health firms catch eyes at BIO San Diego 2022 June 22, 2022 biocat
  • HIGHLIGHTS: BIOSPAIN in Barcelona, biggest round in digital health, new technical facilities, foreign investment in infrastructures and unbridled clinical trials activity May 25, 2022 biocat
  • Catalonia participates in over 1,200 active clinical trials May 17, 2022 biocat
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
  • youtube
© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
Gate2Brain The Mind the Gap program of Botín Foundation invests 1.5 million euros in three...
Scroll to top
Manage Cookie Consent
This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}